Dyadic International (NASDAQ:DYAI) Share Price Passes Below 50 Day Moving Average – What’s Next?

Shares of Dyadic International, Inc. (NASDAQ:DYAI) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $1.13 and traded as low as $1.05. Dyadic International shares last traded at $1.14, with a volume of 32,764 shares traded.

Dyadic International Trading Up 8.6 %

The business has a fifty day moving average price of $1.13 and a 200-day moving average price of $1.42. The company has a quick ratio of 5.39, a current ratio of 5.39 and a debt-to-equity ratio of 1.72. The company has a market cap of $33.61 million, a P/E ratio of -4.07 and a beta of 0.72.

Dyadic International (NASDAQ:DYAI) last issued its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Dyadic International had a negative net margin of 428.86% and a negative return on equity of 145.95%. The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $1.00 million. During the same period in the prior year, the company earned ($0.07) earnings per share. On average, analysts forecast that Dyadic International, Inc. will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Dyadic International

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. grew its holdings in shares of Dyadic International, Inc. (NASDAQ:DYAI) by 2.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 847,301 shares of the biotechnology company’s stock after purchasing an additional 21,000 shares during the period. Chapin Davis Inc. owned about 2.90% of Dyadic International worth $1,254,000 at the end of the most recent quarter. Institutional investors own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.